Company Interview / Hydrix finding rhythm with device innovation

Gavin Coote from Hydrix (ASX: HYD) shares that the company is seeing strong financial performance, with two consecutive profitable quarters driven by their Hydrix Services segment. The company has secured a contract extension with Paul Hartman Group, boosting investor confidence.

Gavin highlights Hydrix's focus on medical device innovation, primarily cardiac products. The company's international expansion has been successful, now generating 75% of revenue from Europe and the US. Post-COVID strategies include establishing business development teams overseas.

The future looks promising, with a robust sales pipeline and prospects for substantial revenue growth. Despite some reliance on VC funding, the potential of IPO markets opening up could drive investment in new medical developments. Hydrix aims to close pivotal contracts by the June half.